Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Status: Enrolling
Updated:  5/7/2012
Houston Veterans Administration Medical Center
mi
from
Houston, TX
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Status: Enrolling
Updated: 5/7/2012
Houston Veterans Administration Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Status: Enrolling
Updated:  5/7/2012
Audi L. Murphy VA Hospital
mi
from
San Antonio, TX
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Status: Enrolling
Updated: 5/7/2012
Audi L. Murphy VA Hospital
mi
from
San Antonio, TX
Click here to add this to my saved trials
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Status: Enrolling
Updated:  5/7/2012
Seattle King County Health Department
mi
from
Seattle, WA
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis
Status: Enrolling
Updated: 5/7/2012
Seattle King County Health Department
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Alabama Clinical Therapeutics, 806 St. Vincent's Drive, Suite 615
mi
from
Birmingham, AL
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Alabama Clinical Therapeutics, 806 St. Vincent's Drive, Suite 615
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Madera Family Medical Group,1111 West 4th Street
mi
from
Madera, CA
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Madera Family Medical Group,1111 West 4th Street
mi
from
Madera, CA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Center for Clinical Trials LLC, 16660 Paramount Blvd, Suite 301
mi
from
Paramount, CA
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Center for Clinical Trials LLC, 16660 Paramount Blvd, Suite 301
mi
from
Paramount, CA
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Kentucky Pediatric/Adult Research, 201 south 5th street
mi
from
Bardstown, KY
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Kentucky Pediatric/Adult Research, 201 south 5th street
mi
from
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Bluegrass Clinical Research Inc.5512 Bardstown Road, Suite 2
mi
from
Louisville, KY
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Bluegrass Clinical Research Inc.5512 Bardstown Road, Suite 2
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Ohio Pediatric Research Association, 7371 Brandt Pike, Suite C
mi
from
Huber Heights, OH
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Ohio Pediatric Research Association, 7371 Brandt Pike, Suite C
mi
from
Huber Heights, OH
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Ohio Pediatric Research Association, 1775 Delco Park Drive
mi
from
Kettering, OH
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Ohio Pediatric Research Association, 1775 Delco Park Drive
mi
from
Kettering, OH
Click here to add this to my saved trials
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated:  5/7/2012
Focus Research Group,201 Signature Place
mi
from
Lebanon, TN
Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults
Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations
Status: Enrolling
Updated: 5/7/2012
Focus Research Group,201 Signature Place
mi
from
Lebanon, TN
Click here to add this to my saved trials
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
Status: Enrolling
Updated:  5/8/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults
Status: Enrolling
Updated: 5/8/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute - Phoenix
mi
from
Phoenix, AZ
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute - Phoenix
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of California, Davis Medical Center
mi
from
Sacramento, CA
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of Colorado
mi
from
Denver, CO
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
Johns Hopkins University
mi
from
Baltimore, MD
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
The Mayo Clinic
mi
from
Rochester, MN
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
Saint Louis University Hospital - School of Medicine - Department of Neurology & Psychiatry
mi
from
St. Louis, MO
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
Saint Louis University Hospital - School of Medicine - Department of Neurology & Psychiatry
mi
from
St. Louis, MO
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of New Mexico
mi
from
Albuquerque, NM
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of Toledo
mi
from
Toledo, OH
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of Virginia Health System
mi
from
Charlottesville, VA
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated:  5/10/2012
University of Manitoba - Medical Microbiology and Infectious Diseases
mi
from
Winnipeg,
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)
Status: Enrolling
Updated: 5/10/2012
University of Manitoba - Medical Microbiology and Infectious Diseases
mi
from
Winnipeg,
Click here to add this to my saved trials
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated:  5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated: 5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
Brigham and Women's Hosp
mi
from
Boston, MA
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
Massachusetts General Hospital
mi
from
Boston, MA
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
Umass Memorial Medical Center
mi
from
Worcester, MA
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
Umass Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
Montefiore Medical Center
mi
from
Bronx, NY
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
Fletcher Allen Health Care/University of Vermont
mi
from
Burlington, VT
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
Fletcher Allen Health Care/University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated:  5/14/2012
University of Wisconsin Hospital
mi
from
Madison, WI
BK Treatment Study
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
Status: Enrolling
Updated: 5/14/2012
University of Wisconsin Hospital
mi
from
Madison, WI
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Aurora, CO
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Bridgeport, CT
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Honolulu, HI
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Louisville, KY
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Metairie, LA
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Baltimore, MD
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Rochester, MN
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Helena, MT
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Helena, MT
Click here to add this to my saved trials
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated:  5/14/2012
Clinical Research Facility
mi
from
Omaha, NE
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI
Status: Enrolling
Updated: 5/14/2012
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials